PHVS
Pharvaris N.V.
Set alert
33.53 USD -0.05 -0.15%
33.10 Day range 33.94
21.59 52-week range 38.86
- YTD
- +20.83%
- 1 year
- +50.76%
- Open
- 33.48
- Prev close
- 33.58
- Mkt cap
- 2.35B
- Vol
- 1.48M
- Avg vol
- 786.85K
- EPS
- -3.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 33.10
- High
- 33.94
- Forward P/E
- -10.97
- Beta
- -2.46
- Short ratio
- 3.40
- Inst. own
- 93.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 33.72
- 200-d avg
- 30.96
- 1y target
- 57.52
Key statistics
- Market cap
- 2.35B
- Enterprise value
- 2.04B
- Trailing P/E
- 0.00
- Forward P/E
- -10.97
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.97
- EPS (TTM)
- -3.06
- Beta
- -2.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -90.36M
- Total cash
- 318.28M
- Total debt
- 673.73K
- Return on equity
- -70.46%
- Shares outstanding
- 70.20M
- Short % of float
- 4.26%
- 50-day average
- 33.72
- 200-day average
- 30.96
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 57.52 +71.5% upside
Now 33.53
- Target (low)
- 40.91
- Target (mean)
- 57.52
- Target (high)
- 78.82
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.71909.
Financials — quick view
PHVS Revenue — quarterly 0
PHVS Net income — quarterly -47.84M
PHVS EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.81867 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.7467 | -0.81 | -0.06 | -8.48% |
| May 12, 2026 | Mar 31, 2026 | -0.82187 | -0.70 | +0.12 | +14.83% |
| Apr 2, 2026 | Dec 31, 2025 | -0.71462 | -0.84565 | -0.13 | -18.34% |
| Nov 12, 2025 | Sep 30, 2025 | -0.78 | -0.70 | +0.08 | +10.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | up | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | main | Outperform | Outperform |
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- pharvaris.com
News
- This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
- This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
- This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday
- This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
- Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
- This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
- B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on PHVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABELE STEFAN | Chief Operating Officer | Sale | Sep 14, 2026 | 39,068 |
| BJORK ELISABETH | Director | Sale | Sep 16, 2026 | 15,167 |
| GLASSMAN ROBERT R. | Director | Sale | Sep 16, 2026 | 10,500 |
| LESAGE ANNE SIMONNE J PH.D. | Officer | Sale | Sep 16, 2026 | 0 |
| LU PENG | President | Conversion of Exercise of derivative security | Sep 21, 2026 | 110,261 |
| MODIG BERNDT B.A.E | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.04% | 6,565,272 | 220.13M | Jun 29, 2026 |
| General Atlantic, L.P. | 10.02% | 6,550,757 | 219.65M | Jun 29, 2026 |
| Foresite Capital Management IV, LLC | 7.31% | 4,778,581 | 160.23M | Jun 29, 2026 |
| venBio Partners LLC | 7.10% | 4,643,430 | 155.69M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 5.59% | 3,653,310 | 122.50M | Jun 29, 2026 |
| Eqt Fund Management S.a R.l. | 5.24% | 3,424,609 | 114.83M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.10% | 1,373,193 | 46.04M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.78% | 1,165,414 | 39.08M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.22% | 800,000 | 26.82M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.99% | 644,591 | 21.61M | Jul 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.61% | 400,000 | 13.41M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.61% | 399,479 | 13.39M | Aug 30, 2026 |